Melatonin protects against methamphetamine-induced Alzheimer's disease-like pathological changes in rat hippocampus.

Abstract

Methamphetamine (METH) is a psychostimulant drug of abuse. METH use is associated with cognitive impairments and neurochemical abnormalities comparable to pathological changes observed in Alzheimer's disease (AD). These observations have stimulated the idea that METH abusers might be prone to develop AD-like signs and symptoms. Melatonin, the pineal hormone, is considered as a potential therapeutic intervention against AD. We thus conducted the present study to explore potential protective roles of melatonin against METH-induced deficits in learning and memory as well as in the appearance of AD-like pathological changes in METH-treated male Wistar rats. We found that melatonin ameliorated METH-induced cognitive impairments in those rats. Melatonin prevented METH-induced decrease in dopamine transporter (DAT) expression in rat hippocampus. Melatonin reversed METH-induced activation of β-arrestin2, reduction of phosphorylation of protein kinase B (Akt) and METH-induced excessive activity of glycogen synthase kinase-3β (GSK3β). Importantly, melatonin inhibited METH-induced changes in the expression of β-site APP cleaving enzyme (BACE1), disintegrin and metalloproteinase 10 (ADAM10), and presenilin 1 (PS1), as well as the reduction of amyloid beta (Aβ)42 production. Immunofluorescence double-labeling demonstrated that melatonin not only prevented the METH-induced loss of DAT but also prevented METH-induced Aβ42 overexpression in the dentate gyrus, CA1, and CA3. Furthermore, melatonin also suppressed METH-induced increase in phosphorylated tau. Significantly, melatonin attenuated METH-induced increase in N-methyl-D-aspartate receptor subtype 2 B (NR2B) protein expression and restored METH-induced reduction of Ca2+/calmodulin-dependent protein kinase II (CaMKII). This suggested that melatonin attenuated the toxic effect of METH on the hippocampus involving the amyloidogenic pathway. Taken together, our data suggest that METH abuse may be a predisposing risk factor for AD and that melatonin could serve as a potential therapeutic agent to prevent METH-induced AD like pathology.

• Authors: Pattama Panmak, Chutikorn Nopparat, Kannika Permpoonpattana, Jatuporn Namyen, Piyarat Govitrapong
• Journal: Neurochemistry international (Neurochem Int) Vol. 148 Pg. 105121 (09 2021) ISSN: 1872-9754 [Electronic] England
• PMID: 34224806 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Chemical References

• Amyloid beta-Peptides
• Antioxidants
• Central Nervous System Stimulants
• Neuroprotective Agents
• Methamphetamine
• Melatonin

Topics

• Alzheimer Disease (chemically induced, pathology, prevention & control)
• Amyloid beta-Peptides (metabolism)
• Animals
• Antioxidants (therapeutic use)
• Central Nervous System Stimulants
• Cognitive Dysfunction (chemically induced, prevention & control)
• Hippocampus (drug effects, pathology)
• Learning Disabilities (chemically induced, prevention & control)
• Male
• Maze Learning (drug effects)
• Melatonin (therapeutic use)
• Memory Disorders (chemically induced, prevention & control)
• Methamphetamine
• Neuroprotective Agents (therapeutic use)
• Rats
• Rats, Wistar